Value proposition

TG is a biopharmaceutical company focused on the development of novel treatments for B-cell diseases.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).

Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib